Actively Recruiting
Study of ASP388B Alone and With Standard Cancer Therapies in Patients With Advanced Unresectable or Metastatic Solid Tumors
Led by Astellas Pharma Global Development, Inc. · Updated on 2026-10-26
392
Participants Needed
4
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying ASP388B, a new drug given alone or with standard cancer treatments, in people with locally advanced, unresectable, or metastatic solid tumors. This early-phase study aims to find safe and effective doses of ASP388B and understand which tumor types respond well. The study is conducted in two parts dose escalation and dose expansion, to evaluate safety and dosing in different small patient groups. In Part 1, participants receive increasing doses of ASP388B either alone or combined with standard cancer therapies, all given by intravenous infusion in 21-day cycles. Part 2 uses the best doses from Part 1, also given alone or with standard therapies, to further assess treatment in specific tumor types. Standard therapies are administered according to their approved guidelines. Participants will have health checks and monitoring throughout the study, including tracking any side effects or medical problems. Researchers will measure treatment safety by recording dose-limiting toxicities, adverse events, laboratory and vital sign changes, heart monitoring, physical exams, and performance status up to 45 months. Additional assessments include tumor response, pharmacokinetics, immune cell changes, and antibody development over various timeframes. The total study duration extends until May 2030.
CONDITIONS
Brief Title
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Research Team
A
Astellas Pharma Global Development, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here